#remdesivir injection price

[worldspotlightnews]

ECC refuses to increase price of Remdesivir injection

Pharmacy employees wearing facemasks as a preventive measure against the coronavirus attend to customers in Islamabad, Pakistan, on March 23, 2020. — AFP The Economic Coordination Committee (ECC) of the federal cabinet Monday decided not to increase the price of Remdesivir injection, used for the treatment of COVID-19, Radio Pakistan reported. The ECC, under the chair of Finance Minister Ishaq…

[lok-shakti]

तीस दिन में एक भी रेमडेसिविर की बिक्री नहीं, गोदामों में 73 लाख के इंजेक्शन डंप

तीस दिन में एक भी रेमडेसिविर की बिक्री नहीं, गोदामों में 73 लाख के इंजेक्शन डंप

प्रतीकात्मक तस्वीर। – फोटो : Social media ख़बर सुनें ख़बर सुनें कोरोना की दूसरी लहर में संक्रमितों के लिए संजीवनी माने गए रेमडेसिविर इंजेक्शन की बिक्री अब ठप है। बीते तीस दिनों में एक भी रेमडेसिविर इंजेक्शन की बिक्री नहीं हुई है। स्टाकिस्टों के गोदामों में करीब 73 लाख के इंजेक्शन डंप हैं। कंपनियां सौदे के मुताबिक इंजेक्शन की वापसी लेने को तैयार नहीं हैं। ऐसे में थोक दवा कारोबारियों को इंजेक्शनों…

[getmedsphilippines]

Getmeds.ph is the Philippines' leading online drugstore with a one-stop destination for healthcare products, such as over-the-counter pharmaceuticals, healthcare devices, prescriptions, bath and body, and personal care medicines.

[24x7newsbengal]

Remdesivir price reduced by manufacturers after several states report shortage of key drug

Remdesivir price reduced by manufacturers after several states report shortage of key drug

Image Source : FILE PHOTO/PTI Major manufacturers of Remdisivir have reduced the price considerably. (Photo for representation only) The demand for Remdesivir, an injectable medicine, has soared manifold amid skyrocketing coronavirus cases in the country. Amid reports of several states pressing the alarm button over the acute shortage of the key antiviral drug, manufacturers have now decided to…

[journalistcafe]

सरकार ने घटाएँ दाम, अब सस्ते मे मिलेगी कोरोना की ये दावा

सरकार ने घटाएँ दाम, अब सस्ते मे मिलेगी कोरोना की ये दावा

  कोरोना ने जहां पुरे देश को डरा रखा है, वही उसके इलाज के लिए एक रहत की खबर आ रही है. कोरोना के गंभीर मरीजों के इलाज के लिए इस्तेमाल होने वाली Remdesivir के दामों मे काफी कमी आई है. इसे कंपनिया अभी तक 2800 से 5400 रुपये प्रति इंजेक्शन की एमआरपी पर बेच रहीं थीं, लेकिन अब ये कीमतें 899 से 3490 रुपये प्रति इंजेक्शन के बीच कर दी गई है। राष्ट्रीय औषध मूल्य प्राधिकरण (एनपीपीए) ने एक बयान जारी कर कहा…

[newshindiplus]

कोरोना की कारगर दवा रेमेडिसविर और टोसीलिज़ुमाब के ओवर प्रिसक्रिप्शन पर भारतीय फार्मा विभाग ने जताई आपत्ति

कोरोना की कारगर दवा रेमेडिसविर और टोसीलिज़ुमाब के ओवर प्रिसक्रिप्शन पर भारतीय फार्मा विभाग ने जताई आपत्ति

[ad_1]

एंटी-वायरल ड्रग्स रेमेडिसविर और टोसीलिज़ुमाब के ओवर-प्रिस्क्रिप्शन पर आपत्ति जताई है. सरकारी सूत्रों ने CNBCTV-18 को बताया कि फार्मा विभाग ने एंटी-वायरल ड्रग्स रेमडेसिविर ((Anti-Viral Drugs Remdesivir) ) और टोसीलिज़ुमाब के ओवर-प्रिस्क्रिप्शन पर…

[ddtvnews]

कोरोना की कारगर दवा रेमेडिसविर और टोसीलिज़ुमाब के ओवर प्रिसक्रिप्शन पर भारतीय फार्मा विभाग जताई आपत्ति

कोरोना की कारगर दवा रेमेडिसविर और टोसीलिज़ुमाब के ओवर प्रिसक्रिप्शन पर भारतीय फार्मा विभाग जताई आपत्ति

[ad_1]

एंटी-वायरल ड्रग्स रेमेडिसविर और टोसीलिज़ुमाब के ओवर-प्रिस्क्रिप्शन पर आपत्ति जताई है. सरकारी सूत्रों ने CNBCTV-18 को बताया कि फार्मा विभाग ने एंटी-वायरल ड्रग्स रेमडेसिविर ((Anti-Viral Drugs Remdesivir) ) और टोसीलिज़ुमाब के ओवर-प्रिस्क्रिप्शन पर…

[digimakacademy]

Cipremi launch: कोरोना की एक और दवा लॉन्‍च होने को तैयार, जानिए कितनी होगी कीमत

Cipremi launch: कोरोना की एक और दवा लॉन्‍च होने को तैयार, जानिए कितनी होगी कीमत

[ad_1]

Corona medicine Cipremi by Cipla: सिप्‍ला ने रेमडेसिवीर (Remdesivir) BDR फार्मा से कॉन्‍ट्रैक्‍ट किया था। मार्केट में कोरोना की ये दवा ‘Cipremi’ नाम से बेची जाएगी।

Edited By Deepak Verma | नवभारतटाइम्स.कॉम | Updated: 08 Jul 2020, 01:25:00 PM IST

कोरोना हवा से फैलता है या नहीं? आ गया WHO का पहला बयान हाइलाइट्स

सिप्‍ला ने भी बनाया रेमडेसिवीर का जेनेरिक वर्जन

‘Cipremi’ रखा गया नाम,…

[gahanchintan]

Remdesivir kya hai

Hi,

I am Sandeep, with help of this video I am sharing all the information that I have gathered online about Remdesivir medicine, which has become a very popular name in the Indian market in recent times because of the Corona virus pandemic Covid19 caused by SARs-CoV2 virus. With the help of this video I am trying help, educate and empower the Hindi speaking population as things which have become extremely disastrous would even complicate more for them. People are primarily looking for answers to their question which as follows:

remdesivir injection in hindi price

remdesivir injection in hindi study iq

remdesivir injection kya hai

remdesivir injection price

remdesivir injection price in india

remdesivir coronavirus

remdesivir coronavirus results in hindi

remdesivir pronunciation

remdesivir injection price

remdesivir injection

remdesivir injection kaise

remdesivir injection kaise book kare

remdesivir injection ke fayde in hindi

remdesivir injection kaha milega

remdesivir injection kaha lagana chahiye

Below is the link for the video kindly watch all the videos in the series of these videos and watch each video from start till end and do not forget to share, like and subscribe.

https://youtu.be/7UqkrEyMbOU

[theeurasianpost]

Launch of sukuk plan approved

Launch of sukuk plan approved

ISLAMABAD: The Cabinet on Tuesday approved the launch of the Local and International Monopoly Sukuk Programme on the recommendation of the Finance Division. The Cabinet also approved reducing the price of 100mg Remdesivir injections used in the treatment of Coronavirus from Rs2,308.63 to Rs1,892. Briefing the mediapersons about the decisions taken in the Federal Cabinet meeting along with Prime…

[govtjobspk4u]

Cabinet cuts Remdesivir injection price by 30pc

Cabinet cuts Remdesivir injection price by 30pc

Federal cabinet has approved a reduction in the prices of Remedesivir injection. The injection is used in Covid-19 treatment. The price has been reduced by over Rs1,700 to Rs3,967. Currently, the injection is being sold at Rs5,680. This was announced by Federal Minister for Information and Broadcasting Fawad Chaudhry. He was addressing a press conference after a meeting of the federal cabinet on…

[amitshinde7793]

COVID-19 Impact on Dexamethasone on Healthcare Industry | Data Bridge Market Research

COVID-19 Impact on Dexamethasone on Healthcare Industry

OVERVIEW

A novel coronavirus, SARS-CoV-2, appeared in December 2019 in Wuhan, China, spreading much faster than its predecessors and has already infected millions of patients worldwide as of April 19, 2020. As the scope of the current COVID-19 outbreak has reached the proportion of pandemics, major international efforts in public health are underway to control the outbreak. Although the favorable vaccine was discovered to save the patient life, not everyone gets the dose, so there is considerable interest in repeating existing corticosteroid-based drugs against COVID-19. Several many clinical interpretations of the Randomized Evaluation of COVID-19 Therapy were performed to evaluate useful tool whether dexamethasone is useful for the severe hospitalized patients.

Dexamethasone is a corticosteroid widely used or known for its anti-inflammatory and immunosuppressant activity. Dexamethasone exerts its action in decreasing inflammation by suppressing the migration of cells known as polymorph nuclear leukocytes of PMN and reducing capillary permeability. Through this phenomenon, it stabilizes the cell and lysosomal membrane. In premature infants, dexamethasone also stimulates increased surfactant production in the lungs. It also can inhibit pro-inflammatory cytokines and prostaglandin synthesis. Moreover, dexamethasone also suppresses the proliferation of lymphocytes through direct cytolysis and can inhibit mitosis process of cell division.

IMPACT ON PRICE 

Various market players face many challenges due to the coming of the novel Coronavirus and different strains. One such issue is the uncertainty surrounding the impact of COVID-19 on dexamethasone demands. Due to the increased demand for life-saving drugs such as Tocilizumab, Remdesivir, Favipiravir, Dexamethasone, and several more for coronavirus treatment and stiff competition between the market players.

According to the reports, countries such as India, the U.K., Spain, and many more face second and third waves of Coronavirus due to a sudden surge in demand, and India already grant the use of dexamethasone for severe patients. It looks like as the severity of the COVID infection increases, the dexamethasone usage is also increasing.

According to the reports, the drug cost in U.K. only costs 5 pounds which are needed for ten days, and for the U.S. the cost of this drug is USD 50. Moreover, according to the Health-e News, the regulated price for the injection in South Africa is between R149. 03, and R176.44.

The impact of COVID-19 does not create any major impact on the price of dexamethasone, although some small or developing countries are facing the issue of pricing.

IMPACT ON DEMAND

The Coronavirus zone is the result of various markets around the world. This is the cause of the widespread closures and isolation that are affecting world economic activity. As the cases increase in April, the sudden surge in demand has seen, and the drug went out of stock.

Patient’s families are in a panic situation due to the limited stock of the injection and the higher price of the drug. The injection being sold at a higher price in the black market. In that particular situation, the government takes over the allocation and supply of injection in the different states of India.

Moreover, as the cases increase, the WHO chief pointed out the need for equitable supplies of dexamethasone for possible use in critical patients worldwide as the demand is rising to save the patients. As the India and U.K. regulatory grant, the emergency use of dexamethasone for severe patients the demand is continuously rising after the second wave of Coronavirus hits different countries. WHO also stated that to meet the rising demand for dexamethasone the production facility or capacity must be increased to meet the global demand.

In June 2020, as the University of Oxford releases the clinical results, they demand dexamethasone increases and the orders for dexamethasone surpassed 2.8 million compared to the 397,500 in the month of May 2020. According to Vizient Inc. one of the largest groups for drug purchasing organizations in U.S. hospitals said that as the Oxford clinical studies results on dexamethasone releases, the demand rose by 167%. Vizient Inc. spoke person also said that after the rising demand drug’s makers have been able to fill only about half of hospital orders on time.

The impact of COVID -19 has created an opportunity for the number of clinical research to cure the diseases or related symptoms. The impact of COVID-19 created a positive impact on the dexamethasone market because a number of regulatory bodies approved the emergency use of the drug, and the strong clinical evidence also supports the usage.

IMPACT ON SUPPLY

As the pandemic intensifies, supply chains can be at significant risk due to over-located locations that can potentially be disrupted. The supply chain of drugs has been disrupted. The spread of COVID-19 makes it difficult for governments to use these drugs; the availability of these systems faces constant challenges due to their components of use and limited initial needs.

Due to the sudden surge in cases and rise in demand for the drug, the supply is also increasing. After the U.K. report on dexamethasone usage in COVID-19 patients, a massive surge in demand due to this drug supply also increases. As the WHO stated, the drug is inexpensive, and there are many dexamethasone manufacturers worldwide, who we are confident can accelerate production, so there is no supply chain disruption. One more reason is dexamethasone is only used for critically ill patients or in severe patients. The usage is limited for the patients.

The trade restrictions have chosen nothing more than to produce the necessary medicines domestically during the pandemic, when the increase, counterfeiting, and price increases of imported goods increase. This signifies that even during the COVID-19 pandemic, the market players are able to maintain the supply chain.

The impact of COVID-19 on dexamethasone supply chain was positively affected because it creates an opportunity for researchers and drug manufacturers.

STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS

As the Coronavirus continues to spread to various countries, concerns are growing about drug production and distribution disruptions. Collaborations, agreements, initiatives of market participants such as Fresenius Kabi expand their business to overcome the growing demand for dexamethasone, especially in Indian, U.S., U.K., and highly affected countries. This will help increase the demand for the product among the consumers and thus increase the company's future sales.

·         U.K.-based Oxford University started a clinical trial (Recovery Trial), which is funded by U.K. government showed beneficial results. The results showed that dexamethasone reduces the risk of death by approximately one-third in patients on ventilators and one-fifth in patients receiving oxygen. Moreover, U.K. government also ensures that the lifesaving drugs will be available in NHS healthcare settings with immediate effect

·         World Health Organization (WHO) also closely monitored the supply and demand of dexamethasone across the globe. Moreover, WHO advises the scale-up production of dexamethasone for the continuous supply of drugs

·         German drug manufacturer “Fresenius Kabi” spoke person also stated that we are confident to meet customers’ needs with COVID-related medicines such as dexamethasone. Moreover, the company also stated that they have a good inventory on hand of the steroid and is ramping up production in three of its U.S. factories to meet the surging demand

·         In Boston, Massachusetts General Hospital, infectious disease specialist “Arthur Kim”, stated that we revised our treatment protocol for the recommendation of dexamethasone for patients with severe COVID-19 who require supplemental oxygen

The increasing demand and increasing sale of dexamethasone drugs are fueling the growth of dexamethasone drug market in the near future.

Market participants are involved in the production of dexamethasone drugs, expanding their business through various programs, including collaboration, contracts, pipeline development, collaboration, and market expansion. It is expected that the strategic decisions of these companies will provide significant opportunities for market participants operating in the dexamethasone market.

CONCLUSION

The available clinical evidence suggests that dexamethasone is relatively safe with minimum side effects. Moreover, studies showed that when dexamethasone is administered, it reduces one-third of the risk for patients on ventilators and one-fifth risk for patients on oxygen supply and reduces 35% mortality benefit in certain patients with COVID-19 who are severely ill. However, the FDA still does not approve dexamethasone's use on severe patients, but doctors recommend the usage to save the patient life.

Moreover, ongoing trials are evaluating the use of dexamethasone for the treatment of COVID-19. Government and pharmaceutical market players have also taken strategic initiatives to overcome the pandemic.

[rishabh3210blog]

Asia-Pacific Generic Drugs Market 2021: Top Industry Players, Growth Report to 2027

Asia-Pacific generic drugs market is estimated to grow at a CAGR of nearly 8.0% during the forecast period. A significant rise in the prevalence of chronic diseases is the major factor accelerating the demand for generic medicines in the region. As per the estimation by the World Health Organization (WHO), the number of new cancer incidences expected to be reported in china was nearly 4.6 million in 2020. Further, the National Cancer Registry Programme estimates that there will be 13.9 lakh new cancer incidences reported in India in 2020, which is expected to rise to 15.7 lakh by 2025.

(Get 15% Discount on Buying this Report)

Get Report Sample Copy @ https://www.omrglobal.com/request-sample/asia-pacific-generic-drugs-market

This, in turn, is leading to increasing demand for generic drugs in these countries. Cost is the major benefit associated with the use of generic drugs. The cost of generic drugs can be up to 85% lower compared to the brand-name drug. Generic drug firms do not have to invest in high initial drug development costs which results in the low cost of these drugs compared to branded drugs. The low cost of generics is acting as a major factor accelerating market growth.

A Full Report of Asia-Pacific Generic Drugs Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-generic-drugs-market

Scope of the Asia-Pacific Generic Drugs Market

Market Coverage

Market number available for 2019-2026

Base year- 2019

Forecast period- 2020-2026

Segment Covered- By Application and Route of Administration

Regions Covered- China, India, Japan, and Rest of Asia-Pacific

Competitive Landscape- Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Ltd., Aurobindo Pharma Ltd., and Sun Pharmaceutical Industries Ltd.

Recent Strategic Initiatives in the Asia-Pacific Generic Drugs Market

In July 2020, Cipla declared the launch of its generic version of antiviral drug remdesivir, Cipremi, at $53.3 per 100 mg vial. This makes it among the lowest cost versions for COVID-19 treatment and Cipla is looking to deliver more than 80,000 vials within the first month.

In July 2020, Mylan launched a generic version of Remdesivir drug, Desrem, in India for treatment of COVID-19 patients. This drug will be available at a price of nearly $64.2 per 100 mg vial as against Hetero’s Covifor at nearly 72.2 per 100 mg vial and Cipla’s Cipremi costing nearly $53.3 per 100 mg vial.

Asia-Pacific Generic Drugs Market-Segmentation

By Application

Cancer

CVD

Musculoskeletal Diseases

Infectious Diseases

Neurology

Diabetes

Others

By Route of Administration

Oral

Topical

Injectable

Inhaler

Asia-Pacific Generic Drugs Market– Segment by Country

China

Japan

India

Rest of Asia-Pacific

Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-generic-drugs-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: anurag@omrglobal.com Contact no: +91 780-304-0404

[sidnazpro2020]

Hyderabad: Two arrested, 18 remdesivir vials seized | | Live Newspaper Hyderabad

Hyderabad: Two arrested, 18 remdesivir vials seized | | Live Newspaper Hyderabad

HYDERABAD: Task Force police on Tuesday arrested two persons in Bahadurpura for selling remdesivir injections at Rs 20,000 each. Police recovered 18 injections from the accused duo — Salman Raju and Aravind. During questioning, the duo confessed that they were procuring the vials from Shiva Shankar of Attapur and selling them at a higher price. Aravind, who is a native of Guntur in AP, is a…

[expressnewshyderabad]

COVID-19: Seven held for black marketing anti viral drugs #Hyderabad The sleuths of Commissioner's Task Force, North Zone Team conducted simultaneous raids in the limits of Panjagutta, Banjara Hills and SR Nagar areas and apprehended seven persons who were illegally procuring and selling Remdesivir injections (Covifor). According to the DCP Task force P Radhakishen Rao, on specific information the task force north zone team e apprehended Sunku Damodar,Putta Ramalingesh,Busam Girish Kumar,Grandhi Gouri Shankar,Grandhi Harish Kumar,Potnuru Mukunda Rao,Arakanti Chinna after they were indulging in illegal business of COVID-19 anti viral drugs. Remdesivir is an antiviral drug that is being used for the treatment of COVID-19 patients. Due to its high demand, it is not easily available in the market. As the Covid-19 pandemic situation the demand for the Remdesivir "Covifor" has increased. It is normally does not cost more than Rs. 3,500/- depending on manufacture. The Accused persons hatched a plan to earn quick money by illegally procuring the Remdesivir injections in low price thorough known sources or medical staff and selling the same on high price in black market without any valid documents to customers and gain easy money illegally. The accused persons are doing Medical business, and Medical representatives in hospitals. The accused persons used their credentials to target gullible people who needed remdesivir injections for their family members Covid treatment, then the accused persons sell a vial between Rs. 25,000/- and Rs. 35,000/- . The task force police have arrested and seized anti viral drugs from their possession and for further action they were handed over to the SR Nagar police station. https://www.instagram.com/p/CO6hIleL4-A/?igshid=ytjc9xj6fsp5

[adminnewstrust24]

Tamil Nadu: Gunda Act will be imposed on hoarding of Remdesivir and selling oxygen at a higher price, CM Stalin announced

Tamil Nadu: Gunda Act will be imposed on hoarding of Remdesivir and selling oxygen at a higher price, CM Stalin announced

Chennai: Chief Minister MK Stalin said on Saturday that action will be taken against the hoarders of Remedisvir, a drug used in the treatment of Covid-19 patients in Tamil Nadu and those who sell oxygen cylinders at a higher price. This instruction from the Chief Minister to the police has come after reports of some people allegedly selling Remdesivir injection vials at a high price and their…